Clinical Trials Logo

Relapsed Solid Neoplasm clinical trials

View clinical trials related to Relapsed Solid Neoplasm.

Filter by:
  • None
  • Page 1

NCT ID: NCT05060276 Withdrawn - Solid Tumor, Adult Clinical Trials

Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors

Start date: December 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors.

NCT ID: NCT04900519 Recruiting - Solid Tumor Clinical Trials

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Start date: November 24, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.

NCT ID: NCT04773782 Recruiting - CNS Tumor Clinical Trials

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Start date: February 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to < 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA and/or KIT mutation (including non-synonymous point mutations, insertions, and deletions) or amplification, or DMG-H3K27a who have no available curative treatment options. This is a single-arm trial in which all participants will receive avapritinib. The study consists of 2 parts: dose confirmation, safety, and PK (Part 1) and initial efficacy, safety, and PK at the Part 2 recommended dose (Part 2).